Comparison of Efficacy, Safety, and Economic Outcomes Between Biosimilar ABP 215 and Originator Bevacizumab in Japanese Patients With Colorectal Cancer

Takahiro Sumimoto; Ryota Tanaka; Ryosuke Tatsuta; Miki Kubota; Hiroki  Itoh; Takahiro Sumimoto; Ryota Tanaka; Ryosuke Tatsuta; Miki Kubota; Hiroki  Itoh

doi:10.7759/cureus.72260

Enter your email address to receive your free PDF download.

Please note that by doing so you agree to be added to our monthly email newsletter distribution list.

Sign up for Cureus

or

First name

Last name

Email

Password

Specialty

Email Communication and Personal Data

Cureus personal data will never be sold to third parties and will only be used to enrich the user experience and contact you in direct relation to the application. I agree to opt in to this communication.

Learn more

Learn more

Learn more

Learn more

Learn more

Learn more

Ongoing Competitions

Enter your email address to receive your free PDF download.

Sign in to Cureus

Sign up for Cureus

Email Communication and Personal Data

Download Cureus Media Kit